| 产品描述： | CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects |
| 靶点： |
Camptothecins |
| 体内研究： |
CL2A-SN-38 偶联抗 Trop-2 人源化抗体 hRS7 (腹腔注射，0.2或0.4mg/kg，每周2次，4周) 均能显著抑制人结肠 (COLO 205) 或胰腺小鼠肿瘤异种移植物模型的肿瘤生长 (Capan-1) |
| 参考文献： |
1. Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69. 2. Thomas M Cardillo, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
0.676 ml |
3.379 ml |
6.758 ml |
| 5 mM |
0.135 ml |
0.676 ml |
1.352 ml |
| 10 mM |
0.068 ml |
0.338 ml |
0.676 ml |
| 50 mM |
0.014 ml |
0.068 ml |
0.135 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京